Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxine Ajimi

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|April 19, 2026
A Dose-Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D-OptimalityMaxine Ajimi, Benjamin Webb, Graham M Wheeler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2026
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 StudyJohn F R Robertson, Teimuraz Gogitidze, Zaza Katashvili, et al.
The Lancet. Oncology|October 31, 2024
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trialMafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|April 19, 2026
A Dose-Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D-OptimalityMaxine Ajimi, Benjamin Webb, Graham M Wheeler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2026
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 StudyJohn F R Robertson, Teimuraz Gogitidze, Zaza Katashvili, et al.
The Lancet. Oncology|October 31, 2024
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trialMafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki, et al.
Pageof 1